![logo](/logos/MOLN.SW.webp)
Molecular Partners AG
SIX:MOLN.SW
4.77 (CHF) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Molecular Partners AG |
Symbool | MOLN.SW |
Munteenheid | CHF |
Prijs | 4.77 |
Beurswaarde | 158,335,380 |
Dividendpercentage | 0% |
52-weken bereik | 3.04 - 9.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Patrick Amstutz Ph.D. |
Website | https://www.molecularpartners.com |
An error occurred while fetching data.
Over Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CHF)
Cijfers zijn in miljoenen (CHF)